Genscript Biotech (HKSE:01548) Ending Cash Position : HK$1,026 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Ending Cash Position?

Genscript Biotech's Ending Cash Position for the quarter that ended in Dec. 2024 was HK$1,026 Mil.

Genscript Biotech's quarterly Ending Cash Position declined from Dec. 2023 (HK$11,296 Mil) to Jun. 2024 (HK$3,119 Mil) and declined from Jun. 2024 (HK$3,119 Mil) to Dec. 2024 (HK$1,026 Mil).

Genscript Biotech's annual Ending Cash Position increased from Dec. 2022 (HK$7,972 Mil) to Dec. 2023 (HK$11,296 Mil) but then declined from Dec. 2023 (HK$11,296 Mil) to Dec. 2024 (HK$1,026 Mil).

Genscript Biotech Ending Cash Position Historical Data

The historical data trend for Genscript Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Ending Cash Position Chart

Genscript Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

4,876.40

9,210.39

7,972.24

11,296.12

1,026.01

Genscript Biotech Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															7,972.24	10,945.32	11,296.12	3,118.51	1,026.01

Genscript Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Genscript Biotech's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	11243.469	+	-10217.458
	=	1,026

Genscript Biotech's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	3103.894	+	-2077.883
	=	1,026

Genscript Biotech Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

Genscript Biotech Corp is a China-based provider of life science research services and products. it is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, The company estimates that over two-thirds of GenScript valuation is from its ownership stake in Legend.

Executives

Huang Lili	2202 Interest of your spouse
Hu Zhiyong	2201 Interest of corporation controlled by you
Jin Weihong	2201 Interest of corporation controlled by you
Wang Luquan	2401 A concert party to an agreement to buy shares
Wang Ye	2101 Beneficial owner
Zhang Fangliang	2401 A concert party to an agreement to buy shares
Genscript Corporation	2101 Beneficial owner
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Gns Holdings Limited	2101 Beneficial owner
Hillhouse Capital Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd.	2102 Investment manager

Genscript Biotech Headlines

No Headlines